Status:
COMPLETED
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-65 years
Brief Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Treated by Mylotarg
- Provide ICF
Exclusion
Key Trial Info
Start Date :
October 1 2001
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00161668
Start Date
October 1 2001
Last Update
March 15 2007
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Tucson, Arizona, United States, 85404
2
Berkely, California, United States, 94704
3
Burbank, California, United States, 91505
4
Concord, California, United States, 94520